On Wednesday, Spruce Biosciences, Inc. (NASDAQ:SPRB), trading at $0.54, experienced a shift in market expectations as JMP Securities adjusted its rating from Market Outperform to Market Perform. The stock has seen significant volatility this year, with an 81.7% decline year-to-date. The change in stance comes after the company's drug candidate, tildacerfont, did not meet the anticipated outcomes in the Phase 2b CAHmelia-204 trial. According to InvestingPro data, the company's stock currently trades below its Fair Value.
The analyst at JMP Securities provided insight, stating that the move to a neutral position is a result of the unconvincing data from the recent trial. Although there was some indication of effectiveness from twice-daily doses in the separate Phase 2 CAHptain-205 trial, the results were not strong enough to warrant continued investment in the condition known as Congenital Adrenal Hyperplasia (CAH).
InvestingPro analysis reveals the company holds more cash than debt on its balance sheet, with a current ratio of 5.36x, though it's quickly burning through available funds.
Spruce Biosciences has been exploring the potential of tildacerfont, a drug intended for the treatment of CAH, a rare endocrine disorder. However, the recent developments have tempered expectations. The analyst noted that while there is a potential upside from a Phase 2 trial for Major Depressive Disorder (MDD), which is being funded by SPRB’s partner HMNC and is expected to start in the first quarter of 2025, the prospects are considered uncertain due to the drug mechanism's historical failures in this indication.
The downgrade reflects a reevaluation of the biopharmaceutical company's stock following the trial results. The analyst's comments suggest that while there may be opportunities for Spruce Biosciences in the future, the current evidence does not support a higher investment thesis.
In other recent news, Spruce Biosciences has been the focus of investor attention due to the upcoming Phase 2b results for its treatment, tildacerfont. The firm Oppenheimer continues to hold an Outperform rating for Spruce Biosciences, anticipating these key data releases. The results are expected to provide insights into tildacerfont's safety and efficacy at different doses, potentially impacting glucocorticoid usage in adults with congenital adrenal hyperplasia (CAH).
In parallel, Spruce Biosciences is facing a potential delisting from the Nasdaq Stock Market for not meeting the minimum bid price requirement. The company has been granted an additional 180 days until April 21, 2025, to meet the minimum closing bid price of $1.00 per share. The company is considering various strategies to address this, including a potential reverse stock split.
These developments are part of a series of recent events surrounding Spruce Biosciences. The company's stock has experienced significant volatility, declining 81.34% year-to-date. However, Oppenheimer's analysis suggests that the forthcoming data could differentiate tildacerfont from its competitors and potentially revive investor interest in Spruce Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.